ENB THERAPEUTICS, INC.

Profile

Company Names

ENB THERAPEUTICS, INC.

Addresses

C/O LAUNCHLABS, 430 E 29TH ST., 14TH FLOOR, NEW YORK, NY 100116

C/O LAUNCHLABS, 430 E. 29TH ST., 14TH FLOOR, NEW YORK, NY 10016

Phone Numbers

212 792-2317
(212) 792-2317

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2018

State Incorporated:

DELAWARE

Total Amount Raised:

$9,602,084.00

Number of Funding Rounds:

3
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
3
2023-09-22 
$225,000.00 
$1,000,000.00 
$775,000.00 
Debt 
2
2021-01-07 
$1,282,500.00 
$2,600,000.00 
$1,317,500.00 
Debt 
1
2018-09-07 
$8,094,584.00 
$9,094,584.00 
$1,000,000.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
STUART 
 
HWANG 
DIRECTOR
ENB THERAPEUTICS, INC.
SUMAYAH 
 
JAMAL 
EXECUTIVE OFFICER, DIRECTOR
ENB THERAPEUTICS, INC.
FUMITAKA 
 
MORI 
DIRECTOR
ENB THERAPEUTICS, INC.
WALTER 
 
OLESIAK 
DIRECTOR
AXIKIN PHARMACEUTICALS INC   |  REMIGES BIOPHARMA FUND, LP   |  NAPAJEN PHARMA, INC.   |  ENB THERAPEUTICS, INC.
BARBARA 
 
SCHILBERG 
DIRECTOR
ONEHEALTHCOMPANY, INC.   |  ENB THERAPEUTICS, INC.   |  KERITON, INC.   |  MEBIAS DISCOVERY, INC.
ALBERT 
 
SOKOL 
EXECUTIVE OFFICER
ISUBSCRIBED INC.   |  ENB THERAPEUTICS, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2023-10-03
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2023-09-22 
2021-01-11
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2021-01-07 
2020-02-13
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2018-09-07 
2018-09-21
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2018-09-07 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#